Mon panier

Human LAG-3 (Luc) Jurkat Reporter Cell

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
SCJUR-STF065-2Vials (1Vial X 2)
$12410.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

    1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
    2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
    3. Comprehensive application data to support assay development and validation
    4. Full tracible record, stringent quality control and validated cell passage stability
    5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
    6. Global commercial license assistance whenever regulatory filing is required
  • Description

    The Human LAG-3 (Luc) Jurkat Reporter Cell was engineered to not only express the NFAT response element driving luciferase expressing systems, but also express the receptor full length human LAG-3 (Uniprot: P18627-1), which can use to evaluate the potency of LAG-3 blockade. When co-cultured with target cells expressing human MHCⅡ, the LAG-3/MHCⅡ interaction inhibits TCR signaling and NFAT-mediated luminescence. Blocking the LAG-3/MHCⅡ interaction by anti-LAG-3 antibodies releases the inhibitory signals and results in TCR activation and NFAT-mediated luminescence.

  • Application

    • Screen for anti-human LAG-3 antibody.

    LAG-3 Assay Principles

  • Growth Properties

    Suspension

  • Selection Marker

    Puromycin (5 μg/mL) + Hygromycin B (20 μg/mL)

  • Complete Growth Medium

    RPMI-1640 + 10% FBS

  • Freeze Medium

    Serum-free cell cryopreservation medium

  • Quantity

    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

  • Storage

    Frozen in liquid nitrogen.

  • Mycoplasma Testing

    Negative

  • Sterility Testing

    Negative

  • Instructions for Use

    See data sheet for detailed culturing and assay protocol.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • Receptor Assay

     LAG-3 FACS

    Expression analysis of human LAG-3 on Human LAG-3 (Luc) Jurkat Reporter Cell by FACS.
    Human LAG-3 (Luc) Jurkat Reporter Cell or negative control cell were stained with PE-labeled anti-human LAG-3 antibody.

    Protocol
  • Application

     LAG-3 APPLICATION

    Blocking activity of anti-human LAG-3 antibody.
    This reporter cell was incubated with serial dilutions of antibodies in the presence of target cells expressing human MHCⅡ. The EC50 of anti-human LAG-3 antibody was approximately 0.11 μg/mL.

    Protocol
  • Passage Stability

     LAG-3 PASSAGE

    Passage stability analysis by anti-human LAG-3 antibody stimulation.
    The continuously growing Human LAG-3 (Luc) Jurkat Reporter Cell was stimulated with serial dilutions of antibodies in the presence of target cells expressing human MHCⅡ. Anti-human LAG-3 antibody stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 14-38.

    Protocol
*Please contact us if you are interested in related cell pool service.

Avis des utilisateurs
Publier un commentaire

Déclaration importante

  • Limited Use&License Disclosure

    BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

    1. If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
    2. Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
    3. This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    4. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    5. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    6. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Lymphocyte activation gene 3 protein

  • Catégorie:

  • Nombre de médicaments répertoriés:

    1 Détails

  • Nombre de médicaments cliniques:

    32 Détails

  • Étape de développement la plus élevée:

    Approved

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Déclaration importante